FIDE’s conference analysis programs provide subscribers with unprecedented independent insight direct from a network of leading dermatologists into the latest data presented at EADV and AAD. Panel discussion videos and expert insight slides from all our EADV programs are NOW AVAILABLE to subscribers. #psoriasis #atopicdermatitis #hidradenitissuppurativa #vitiligo #alopeciaareata Missed FIDE at EADV 2024? Contact us via [email protected] for access to the insights of an extended network of world-renowned experts into the most impactful data from the congress.
FIDE - Dermatology in Depth
Pharmaceutical Manufacturing
Access independent, unbiased expert insights from the FIDE faculty
About us
FIDE delivers dermatology consulting services and educational programs to the biotechnology, medical device, and pharmaceutical industries, as well as to the wider healthcare industry. We provide our clients with direct and unbiased views on clinical data and offer a full suite of services, including the FIDE Conference Analysis Program (CAP), strategic consulting, competitor analysis, market insight reports, and pipeline and portfolio strategy. Our expertise spans the pathophysiology, clinical presentation, and treatment of chronic dermatology indications, including psoriasis, psoriatic arthritis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo. Our expert-led approach differs from conventional consultancy. We’re a network of more than 25 leading KOLs—including Dr. Bruce Strober, Dr. Ken Gordon and Dr. Richard Langley, that combines the latest therapy area intelligence with strategic consulting to improve healthcare outcomes and optimize business goals. The FIDE program is one several Expert Partnership programs. Visit our website below to view the full FIDE faculty as well as our various programs.
- Website
-
https://expertpartnership.com
External link for FIDE - Dermatology in Depth
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Partnership
- Founded
- 2010
- Specialties
- dermatology, education, insights, vitiligo, alopecia areata, healthcare, hidradenitis superativa, psoriasis, atopic dermatitis, chronic spontaneous urticaria, prurigo nodularis, biotech, and pharma
Locations
-
Primary
Get directions
London, GB
Employees at FIDE - Dermatology in Depth
Updates
-
Hear Ken Gordon's highlights from this year’s EADV conference in the video below. Recorded webcasts and expert insight slides from each of FIDE’s 5 conference analysis programs in psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo will be available to subscribers soon. For more information on how to access these materials, contact us today on LinkedIn or [email protected] #dermatology Expert Partnership
-
Hear Bruce Strober's highlights from this year’s EADV conference in the video below. Recorded webcasts and expert insight slides from each of FIDE’s 5 conference analysis programs in psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo will be available to subscribers soon. For more information on how to access these materials, contact us today on LinkedIn or [email protected] #dermatology Expert Partnership
-
Professor Brian Kirby and other members of the FIDE HS faculty recently collaborated with Avalere Health to develop an infographic providing clinical perspectives and (insight into ways of enhancing the patient journey) advice on improving patient experience. Details on how to access the document can be found below. To join the discussion at #EADV please contact [email protected]
Hidradenitis Suppurativa (HS) is a painful inflammatory skin disease that causes recurrent abscesses, inflammatory nodules, scarring, and chronic suppuration. While promising new treatments are on the horizon, there are still significant unmet needs that must be addressed to ensure every patient can benefit from these innovations. To better understand treatment options, and what needs to be done to improve patient outcomes , download our infographic now. https://bit.ly/4dWjgs9 #HidradenitisSuppurativa #LivingwithHS #PatientJourney #HSResearch
-
Raj Chovatiya, MD, PhD, MSCI recently shared his thoughts on what he is looking forward to discussing with FIDE’s panel of experts at EADV 2024. Join FIDE for exclusive, expert-led discussion and analysis of the most impactful abstracts presented at EADV 2024 and understand how their clinical implications may shape future patient management. Reach out to us via LinkedIn or via FIDE.net/contact for more information. #dermatology #Immunology Expert Partnership
-
Join FIDE in person at EADV 2024 to hear the independent insights of leading experts into new data presented at the congress. For more information, please contact [email protected]
-
Alan Irvine MD DSc recently shared his thoughts on what he is looking forward to discussing with FIDE’s panel of experts at EADV 2024. Join FIDE for exclusive, expert-led discussion and analysis of the most impactful abstracts presented at EADV 2024 and understand how their clinical implications may shape future patient management. Reach out to us via LinkedIn or via FIDE.net/contact for more information. #dermatology #immunology Expert Partnership
-
Bruce Strober recently shared his thoughts on what he is looking forward to discussing with FIDE’s panel of experts at EADV 2024. Join FIDE for exclusive, expert-led discussion and analysis of the most impactful abstracts presented at EADV 2024 and understand how their clinical implications may shape future patient management. Reach out to us via LinkedIn or via FIDE.net/contact for more information. #dermatology #immunology Expert Partnership
-
For more information on how to join FIDE's conference analysis programs, contact [email protected]
-
Outputs from FIDE’s first Early-stage Development Forum are NOW AVAILABLE. Our experts recently delivered their insights into the latest Phase 1 and 2 data for novel pipeline therapies, helping industry subscribers: •Inform early-phase clinical and strategic decision making •Identify differentiation opportunities versus established therapies •Optimize the development of novel therapeutics Check out what was covered during the event in the summary below, and contact [email protected] for access to the discussion and clinical insights slide deck